Illumina’s US$7b Grail deal vetoed by European Union
ILLUMINA’S US$7 billion takeover of cancer-test provider Grail was vetoed by the European Union amid concerns that the deal would have hampered competition.
The European Commission, the bloc’s merger watchdog, said in a statement the deal would have “stifled innovation and reduced choice” in the emerging market for blood-based early cancer detection tests. Illumina’s proposed remedies failed to allay the EU’s concerns.
“Illumina is currently the only credible supplier of a technology allowing to develop and process these tests,” EU Antitrust Commissioner Margrethe Vestager said in the statement. “With this transaction, Illumina would have an incentive to cut off Grail’s rivals from accessing its technology, or otherwise disadvantage them.”
The deal has been mired in regulatory controversy on both sides of the Atlantic. Grail was spun off from DNA sequencing giant Illumina in 2016 to develop a blood test to detect 50 types of early stages of cancer. Illumina sought to buy back the startup and provoked authorities by closing the deal in August 2021 despite pending investigations.
Vestager said that Grail is “in a race” with other companies to develop the tests, and if successful, they “will revolutionise our fight against cancer and help to save millions of lives.”
But, she said, “it is vital to preserve competition” between developers “at this critical stage of development” and “as Illumina did not put forward remedies that would have solved our concerns, we prohibited the merger.”
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
The EU warned in July that jumping the gun by closing the deal early was “a serious breach” of procedures and could spark “hefty fines.”
Illumina won a temporary boost last week when it defeated a US Federal Trade Commission lawsuit seeking to unwind the acquisition after an administrative judge ruled the tie-up didn’t violate antitrust law.
The FTC, which is weighing its next steps, argued the deal threatens to slow progress toward earlier cancer diagnosis, as Grail’s rivals also rely on Illumina’s sequencing services.
Earlier this year the company lost an EU court case seeking to topple the commission’s decision to review the deal, arguing the watchdog has no jurisdiction over it and that a potential veto would delay the rollout of cancer tests in the region by many years.
EU deal vetoes are rare. In January it banned Hyundai Heavy Industries’ bid for Daewoo Shipbuilding & Marine Engineering. But that was more than two years after it toppled Thyssenkrupp’s bid for Tata Steel.
The EU’s antitrust arm sparked a political row with France and Germany for thwarting Siemens and Alstom’s project to create a European rail giant. BLOOMBERG
Share with us your feedback on BT's products and services
